Xyloglucan for the treatment of actue diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial

dc.contributor.authorGnessi, Lucio
dc.contributor.authorBacarea, Vladimir
dc.contributor.authorMarusteri Marius
dc.contributor.authorPiqué i Clusella, Núria
dc.date.accessioned2016-11-29T17:51:02Z
dc.date.available2016-11-29T17:51:02Z
dc.date.issued2015-10-30
dc.date.updated2016-11-29T17:51:08Z
dc.description.abstractBackground: There is a strong rationale for the use of agents with film-forming protective properties, like xyloglucan, for the treatment of acute diarrhea. However, few data from clinical trials are available. Methods: A randomized, controlled, open-label, parallel group, multicentre, clinical trial was performed to evaluate the efficacy and safety of xyloglucan, in comparison with diosmectite and Saccharomyces in adult patients with acute diarrhea due to different causes. Patients were randomized to receive a 3-day treatment. Symptoms (stools type, nausea, vomiting, abdominal pain and flatulence) were assessed by a self-administered ad-hoc questionnaire 1, 3, 6, 12, 24, 48 and 72 h following the first dose administration. Adverse events were also recorded. Results: A total of 150 patients (69.3 % women and 30.7 % men, mean age 47.3 ± 14.7 years) were included (n = 50 in each group). A faster onset of action was observed in the xyloglucan group compared with the diosmectite and S. bouliardii groups. At 6 h xyloglucan produced a statistically significant higher decrease in the mean number of type 6 and 7 stools compared with diosmectite (p = 0.031). Xyloglucan was the most efficient treatment in reducing the percentage of patients with nausea throughout the study period, particularly during the first hours (from 26 % at baseline to 4 % after 6 and 12 h). An important improvement of vomiting was observed in all three treatment groups. Xyloglucan was more effective than diosmectite and S. bouliardii in reducing abdominal pain, with a constant improvement observed throughout the study. The clinical evolution of flatulence followed similar patterns in the three groups, with continuous improvement of the symptom. All treatments were well tolerated, without reported adverse events. Conclusions: Xyloglucan is a fast, efficacious and safe option for the treatment of acute diarrhea.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec655488
dc.identifier.issn1471-230X
dc.identifier.pmid26518158
dc.identifier.urihttps://hdl.handle.net/2445/104277
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12876-015-0386-z
dc.relation.ispartofBMC Gastroenterology, 2015, vol. 15, p. 153
dc.relation.urihttps://doi.org/10.1186/s12876-015-0386-z
dc.rightscc-by (c) Gnessi, Lucio et al., 2015
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Biologia, Sanitat i Medi Ambient)
dc.subject.classificationDiarrea
dc.subject.classificationVòmit
dc.subject.classificationDolor abdominal
dc.subject.classificationMedicaments
dc.subject.classificationAssaigs clínics
dc.subject.otherDiarrhea
dc.subject.otherVomiting
dc.subject.otherAbdominal pain
dc.subject.otherDrugs
dc.subject.otherClinical trials
dc.titleXyloglucan for the treatment of actue diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
655488.pdf
Mida:
1.07 MB
Format:
Adobe Portable Document Format